8 Amendments of Cristian Dan PREDA related to 2016/2057(INI)
Amendment 11 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Stresses that some of the barriers to accessing medicines in developing countries include lack of infrastructure, poor quality pharmaceuticals (which are harmful and foster drug resistance), resource constraints, weak pharmaceutical policies, poorly managed supply chains, lack of trained healthcare workers, pricing and limited access to social protection schemes; underlines therefore that the issue of access to medicines in the developing world has to be seen in a broader context and urges the EU to step up efforts to improve countries capacities and help them design working health systems, that aim at improving access to services, particularly for the vulnerable communities;
Amendment 20 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1b. Recalls that SDG target 3.b demands all countries to support the research and development of vaccines and medicines for the communicable and non- communicable diseases that primarily affect developing countries and to provide access to affordable essential medicines and vaccines; calls on EU institutions and Members states to give high priority to these issues;
Amendment 30 #
Draft opinion
Paragraph 2
Paragraph 2
2. Urges not to use free trade agreements with low- and middle-income countries (LMICs) to introduce TRIPS- plus intellectual property (IP) rules that extend monopoly protection, and not to introduce new IP enforcement rules or investment protection to the detriment of access to medicinesAcknowledges that intellectual property plays an important role in the development of new medicines and represents therefore a tool to improve availability of medicines; takes the view that the international intellectual property system must reflect in a balanced way the concerns of the least developed countries (LDC) regarding access to medicines; notes the decision of 6 November 2015 of the WTO TRIPS Council to extend drug patent exemption for LDCs until January 2033;
Amendment 41 #
Draft opinion
Paragraph 3
Paragraph 3
3. Supports competition in generic medicines, which allowscan contribute to broader access to medicines in LMICs; calls, in particular, for the EU to support actively government and encourages tphat use the available legal measures, including TRIPS safeguards and flexibilities, to protect and promote public health; calls also for the EU rmaceutical companies to factor immediately stop targeting countries such as India that have implemented progressive TRIPS-compliant IP policies which promote access to medicines, through its watch-list of ‘priority countries’n their business models the issue of access to medicines in the developing world;
Amendment 53 #
Draft opinion
Paragraph 4
Paragraph 4
Amendment 65 #
Draft opinion
Paragraph 5
Paragraph 5
5. Urges to take advantage of the ongoingTakes notes that the REFIT review process of the EU Tiered Pricing Regulation to repeal it unless it can be amended, in close collaboration with the Commission’s Directorates- General for International Cooperation and Development (DG DEVCO) and for Health and Food Safety (DG SANTÉ), in order to support all measures that countrihas concluded that this legislation still has a role to play in the context of the overall EU strategy to promote an ambitious global health agenda and better access to medicines in poor countries; underlines thave at their disposal to ensure affordable ac EU Tiered Pricing Regulation remains a valuable instrument to promote lower pricess to medicinin developing countries.;
Amendment 76 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Urges the EU to step up its support to the global programs promoting access to medicines in developing countries, whether through the World Health Organization or public-private partnerships such as the Global Fund to fight AIDS, Tuberculosis and Malaria or the Gavi Alliance, which have been instrumental in advancing health goals and greatly improved access to medicines; welcomes, from this perspective, the recently approved increase of the EU contribution to the Global Fund;
Amendment 83 #
Draft opinion
Paragraph 5 b (new)
Paragraph 5 b (new)
5b. Highlights the critical need to develop local capacities in terms of pharmaceutical research and medicines production in developing countries; calls for support to innovative ways to address this issue, such as the development of product development partnerships and open centres of research and production in the developing world;